Charles Craddock and David Sallman discuss transplantation and immunotherapies in AML, focusing on patient eligibility, challenges in CAR-T therapy, targeting pre-transplant minimal residual disease, and improving patient outcomes through DLI and gamma delta T cells. They also explore the design of a randomized study evaluating prophylactic DLI in high-risk AML patients.

Doctors David Sallman and Andrew Brunner discuss updates in myelodysplastic syndromes at ASH 2022. Topics include treatment options for lower-risk and higher-risk disease, trial updates, novel classification systems, and therapies after failure to hypomethylating agents.

Experts Richard Stone and David Sallman discuss novel targets, combinations, and treatment strategies in AML. They explore the potential of drugs Eptenoprop and Magrolumab for TP53-mutated AML, and the importance of mature data sets and specific population focus in phase three trials. The use of complete remission rate as a primary endpoint for TP53 mutant patients is questioned, and CD47 inhibition as a potential therapy is explored.